Drug Development

Inhaled vaccines must resist degradation and penetrate the mucosal lining in the airways and lungs.

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

Sosei Heptares and Eli Lilly have entered a multi-target collaboration and license agreement in diabetes and metabolic diseases.

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Emmes’ new facility is designed to support clients conducting cell and gene therapy research worldwide.

Generate Biomedicines published a preprint describing technology that can generate novel proteins towards desired functional or other properties.

In this episode of the Drug Solutions Podcast, Chris Spivey interviews executives at Shabas Solutions LLC, who ran the overseas QMM pilot project.

Advancing digital transformation can significantly reduce R&D costs and shorten drug discovery timelines.

Unique solutions are required to protect inherently unstable messenger RNA.

Although well known in R&D, PK/PD studies are an equally powerful tool for promoting successful biologic drug development.

Pharmaceutical Technology Europe got the scoop on Agilent's new Dissolution Testing Centre of Excellence in Craven Arms, UK.

Dissolution testing is experiencing a refresh thanks to a variety of market drivers.

Science news can be just so weird, or weirdly useful, that everything else recedes as we ponder whether it is true and what consequences it might bring.

Results from Eisai and Biogen’s Alzheimer's treatment, lecanemab, indicated significantly slowed cognitive decline in patients relative to placebo.

SPX-001, a respiratory drug candidate, will be submitted through a combined Clinical Trial and Ethics Committee application for further advancement in the clinical stages.

Biotech startup, Cradle, has raised $5.4 million in seed funding with an AI-enabled design platform that allows for the synthetic building of cell factories to produce proteins.

Wednesday, November 16, 2022 at 11 am ET | 8 am PT | 4 pm GMT | 5 pm CET This webinar will discuss challenges and key considerations for spray-dried formulations for inhalation, along with a review of current technologies and approved products utilizing particle engineering approaches.

A look back at challenge and innovation highlights in 2022 for oral solid dosage forms, this podcast episode will review industry experts’ takes on factors driving the evolution of OSD forms as well as innovations in APIs, technology, and methodology.

Tuesday, November 15th, 2022 at 10 am EDT | 8 am CDT | 7 am PD Spatial Biology is changing the drug development landscape. Validating efficacy with and actual image of the molecule interacting with the tissue provides the additional data needed to determine success or failure. Join the webinar on November 15th to learn more about the solutions Spatial Biology provides.

Advancements in soft capsule technology can enable the development of soft capsule formulations, which are becoming the preferred method of oral administration.

High-concentration injectable formulations present unique challenges.

Opportunities and developments in particle engineering are providing developers with the tools to advance drug candidates successfully.

The state of oral solid dose manufacturing is influenced by new approaches, novel technologies, and the structural evolution of the raw materials market.

Adherence to detail and thorough project management are required for successful tech transfer and scale up.

Pharma companies set goals and adopt more sustainable alternatives.

New medications show exciting outcomes for weight loss.

Experts discuss factors that can affect the outcome of an ADME study, signs that a drug compound shows promise, red flags, and key parameters to determine safety and efficacy.

FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program.

Gerresheimer has developed a new dropper insert for ophthalmic formulations that it is showcasing at CPHI 2022 in Frankfurt, Germany.